Activates Receptors
Activates melanocortin receptors in the brain that are involved in sexual desire and arousal.
$249.00
A prescription bremelanotide lozenge designed to support sexual desire, arousal, and libido through central nervous system pathways.
Supports sexual desire: Bremelanotide activates central melanocortin pathways involved in sexual motivation and response.
Supports sexual arousal: Acts on nervous-system pathways associated with arousal and sexual response.
Works independently of blood-flow pathways: Unlike PDE5 inhibitors, PT-141 primarily targets central sexual-response pathways rather than vascular erectile function.
Convenient non-injectable delivery: Provides a troche option for clinician-directed bremelanotide treatment.
Blood pressure: Bremelanotide can cause temporary increases in blood pressure and changes in heart rate. According to the supplied product information, this formulation is not recommended for individuals with uncontrolled blood pressure.
Cardiovascular disease: According to the supplied product information, this formulation is not recommended for individuals with cardiovascular disease. Patients with a history of heart disease, heart attack, stroke, high blood pressure, significant arrhythmias, or other cardiovascular conditions should discuss their history with their clinician.
Pregnancy & breastfeeding: This formulation is not recommended during pregnancy or breastfeeding.
Nausea: Nausea is a recognized adverse effect of bremelanotide. Significant or persistent nausea or vomiting should be reported to the prescribing clinician.
Pigmentation changes: Bremelanotide has been associated with focal hyperpigmentation, including the face, gums, breasts, and other localized areas. Some pigmentation changes may not completely resolve after discontinuation.
Oral sensitivity: Because the troche dissolves in the mouth, some individuals may experience gum irritation, altered taste, burning, oral sensitivity, or mucosal irritation.
Potential side effects may include:
Individual response and tolerability may vary.
Bremelanotide activates melanocortin receptors in the nervous system. Its effects on sexual response are believed to involve central melanocortin signaling, particularly pathways associated with the MC4 receptor.
Bremelanotide acts on neural pathways involved in sexual motivation, desire, and arousal. An FDA-approved injectable bremelanotide product exists for acquired, generalized HSDD in certain premenopausal women, but this compounded troche is a different formulation and is not FDA-approved. Individual response varies.
Sildenafil and tadalafil are PDE5 inhibitors that primarily support erectile function by increasing genital blood flow through nitric oxide-cGMP signaling. PT-141 works differently, acting primarily through melanocortin receptors in the central nervous system and targeting pathways associated with sexual desire and arousal.
No. PT-141 is a peptide melanocortin receptor agonist, not a sex hormone. It does not directly replace testosterone, estrogen, or progesterone.
Compounded PT-141 may be incorporated into clinician-directed sexual-health protocols for men or women when a licensed clinician determines treatment is appropriate. FDA-approved bremelanotide, however, has a specific indication for acquired, generalized HSDD in certain premenopausal women and is not approved to treat sexual dysfunction in men.
Yes. Bremelanotide can cause temporary increases in blood pressure, making blood-pressure control and cardiovascular history important considerations before treatment.
Follow the exact administration instructions provided with your prescription. The compounded troche is designed to dissolve in the mouth.
No. This compounded PT-141 (Bremelanotide) Lozenge is not FDA-approved. It is a 5 mg troche and should not be considered interchangeable with the FDA-approved subcutaneous bremelanotide product.
PT-141 Lozenge is a compounded 5 mg bremelanotide troche designed to dissolve in the mouth.
Bremelanotide is a peptide that activates melanocortin receptors in the central nervous system and influences pathways involved in sexual motivation, desire, and arousal.
The troche provides a convenient non-injectable option for clinician-directed bremelanotide treatment.
This compounded PT-141 Lozenge is not FDA-approved and is not interchangeable with FDA-approved injectable bremelanotide.
All dosing should follow the instructions provided by the prescribing clinician.
PT-141 works through the melanocortin receptor system, with its sexual-response effects believed to involve central nervous system pathways associated with the MC4 receptor.
Activates melanocortin receptors in the brain that are involved in sexual desire and arousal.
Influences nerve signaling pathways associated with sexual motivation and response.
Works through the central nervous system rather than primarily increasing blood flow like traditional erectile dysfunction medications.
Acts through non-hormonal pathways without directly replacing or increasing testosterone, estrogen, or progesterone.
Sexual desire is complex and can be influenced by hormonal changes, medications, stress, sleep, mood, relationship factors, pain, and other medical or psychological factors. Persistent or distressing changes in libido may benefit from broader clinical evaluation.
All dosing should follow the instructions provided by the prescribing clinician.
PT-141 Lozenge contains bremelanotide, a melanocortin receptor agonist that acts primarily through central nervous system pathways involved in sexual motivation and arousal. Bremelanotide interacts with melanocortin receptors, particularly MC4R, and may influence neural signaling associated with sexual desire and response rather than acting primarily through vascular blood-flow pathways. This central mechanism distinguishes PT-141 from PDE5 inhibitors such as sildenafil and tadalafil, which primarily target nitric oxide–cGMP signaling and genital blood flow.
